Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: RCJIII who wrote (18349)	5/15/1998 12:22:00 PM
From: Jack of All Trades	Read Replies (1) \| Respond to of 34592

MDMI spread .05 X .12 Shorts are caught they sold a whole bunch at .06! EDIT they are playing games .05 X .10!

To: RCJIII who wrote (18349)	5/15/1998 12:22:00 PM
From: Leman	Read Replies (3) \| Respond to of 34592

ATLC SOURCE: Bausch & Lomb Bausch & Lomb and Atlantic Pharmaceuticals Sign Exclusive Worldwide Licensing Agreement for Breakthrough Cataract Removal Technology - Companies Aim to Revolutionize the Way Millions of Cataract Surgeries are Performed - Technology Could Potentially Shorten Surgical Time and Reduce Complications ROCHESTER, N.Y. and RALEIGH, N.C., May 14 /PRNewswire/ -- Bausch & Lomb (NYSE: BOL - news) has signed a worldwide licensing agreement with Optex Ophthalmologics, Inc., and its parent company Atlantic Pharmaceuticals Inc. (Nasdaq: ATLC - news), to complete the development of Catarex(TM), a breakthrough cataract-removal technology invented by Optex. The agreement joins Optex' patented technology with the engineering and marketing expertise of Bausch & Lomb's surgical business unit, one of the market leaders in the ophthalmic surgery industry. Under the terms of the multi-year agreement, Bausch & Lomb Surgical (formerly Chiron Vision and Storz Instrument Company) and Optex will jointly complete the final design and development of the Catarex system. Bausch & Lomb will assume responsibility for commercializing Catarex globally. Atlantic Pharmaceuticals will receive up-front and milestone payments from Bausch & Lomb. In addition, Bausch & Lomb will pay ongoing royalties on sales of Catarex products. Additional terms of the agreement are not being disclosed. ''We are seizing the opportunity to be the leading provider of innovative products that meet the needs of the growing ophthalmic surgical market,'' said Hakan Edstrom, president of Bausch & Lomb Surgical. ''We are delighted that Atlantic Pharmaceuticals has entrusted Bausch & Lomb with the continued development of its breakthrough technology. Catarex has the potential to revolutionize the way doctors perform cataract surgeries. Based on pre- clinical studies, Catarex is expected to make the doctor's work simpler and more efficient, while reducing the patient's risk.'' ''We are extremely excited to be partnering with the world's leading eye- care company,'' said J. D. Lindjord, president and CEO of Atlantic Pharmaceuticals. ''This transaction is significant in that it generates Atlantic's first revenues and validates our strategy of developing promising early stage technologies to the point where a larger partner can license the technology and bring it to market.'' A GROWING NEED FOR THE NEW TECHNOLOGY Cataracts are a natural progressive clouding and hardening of the eye's normally clear crystalline lens. The clouding and hardening of the lens reduces visual acuity and eventually requires surgical correction. About two million cataract removals are performed annually in the U. S. Approximately four million people worldwide are expected to undergo cataract surgery each year. CATAREX SIMPLIFIES CATARACT REMOVAL Currently most surgeons remove cataracts by using phacomulsification technology, or ''phaco,'' a safe and effective technique introduced 25 years ago. However, phaco requires a high degree of training and skill in order to avoid a few inherent complications which are not anticipated with the new Catarex technology. With phaco, a surgeon must maneuver an ultrasonic probe within the lens capsule (the sac containing the lens) to seek out and break up the hard tissue that constitutes the cataract into fine pieces which are then gently suctioned out of the eye. The ultrasonic probe can occasionally generate heat which can damage tissue around the incision, while the movement of the probe, or the sculpting of the lens, in the confined space can damage the lens capsule if the probe inadvertently comes into contact with it. While such complications are rare, surgeons welcome alternative approaches that would further reduce their occurrence. The Catarex method is a one-step process with a probe that can be held relatively motionless at the entrance to the lens capsule as the lens tissue is drawn to it. The Catarex probe is a rotary device that operates at speeds of 30,000 to 70,000 revolutions per minute, creating a vortex which draws the cataract material to the probe and then mechanically liquefies it. The stationary positioning of the probe is expected to reduce the risk of damage to the lens capsule. Also, clinical studies are expected to show that the Catarex probe generates very little heat, thereby substantially reducing the risk of tissue damage from burns. AN EVEN FASTER PROCEDURE Catarex could also reduce the time for removal of the cataract, which would increase the efficiency and safety of the procedure. A typical phaco procedure takes 4 to 12 minutes to complete, while the Catarex device has the potential to remove a cataract in just 1 to 3 minutes. NEW LENSES AN EVENTUAL POSSIBILITY